The kidney maintains the vital functions of clearing excess body fluid and removing metabolic and exogenous toxins from the blood
The kidney is particularly vulnerable to drugs and other agents that cause renal damage
The heart pumps approximately 25% of cardiac output into the kidneys
Any drug in the blood will eventually reach the highly vascularized kidneys
It may potentially cause drug induced renal failure
If the drug is primarily cleared by the kidney, the drug will become increasingly concentrated as it moves from the renal artery into the smaller vasculature of the kidney
The drug may be filtered or secreted into the lumen of the renal tubules
The concentrated drug exposes the kidney tissue to far greater drug concentration per surface area
Drug-induced kidney disease or nephrotoxicity (DIN) is a relatively common complication of several diagnostic and therapeutic agents.
This presentation discusses drug-induced nephrotoxicity. It defines nephrotoxicity as toxicity in the kidneys caused by toxic chemicals and medications. It identifies several risk factors for drug-induced nephrotoxicity including patient factors like age and pre-existing kidney disease, as well as drug-related factors like dose and interactions. Common clinical signs include decreased urine output and kidney function. Many drugs cause nephrotoxicity through tubular cell toxicity, rhabdomyolysis, or altered blood flow in the kidneys. General measures to prevent nephrotoxicity include adjusting drug dosages, avoiding toxic combinations, ensuring hydration, and using alternative non-nephrotoxic drugs when possible.
The document discusses Drug Induced Kidney Disease (DIKD), specifically drug induced nephrotoxicity. It notes that DIKD is a common complication of various therapeutic agents that can cause abnormalities in acid-base balance, electrolytes, urine sediment, decline in glomerular filtration rate, and increased creatinine and BUN. It identifies several classes of drugs that commonly cause nephrotoxicity like aminoglycosides, amphotericin B, and cisplatin. It also discusses risk factors, clinical presentation, prevention, and various pathological mechanisms of nephrotoxicity including tubular epithelial cell damage, acute tubular necrosis, osmotic nephrosis, and hemodynamically mediated kidney
Renal dialysis is a process that artificially performs the functions of the kidneys for patients with kidney failure. There are two primary types of dialysis - hemodialysis, which uses an external dialysis machine to filter blood outside the body, and peritoneal dialysis, which uses the peritoneal membrane in the abdomen as a filter. Dialysis removes waste and regulates fluid and electrolyte levels by processes of diffusion, ultrafiltration, and osmosis across a semi-permeable membrane. Dialysis is a life-sustaining treatment for end-stage kidney disease.
Drug induced kidney disease (DIKD) is caused by drugs and characterized by increased serum creatinine and blood urea nitrogen levels that are temporally related to drug exposure. Acute tubular necrosis is the most common cause of DIKD in hospitalized patients. Risk factors include increased age, pre-existing kidney disease, use of multiple nephrotoxic drugs, and critical illness. Common culprit drugs are aminoglycosides, radiographic contrast media, nonsteroidal anti-inflammatory drugs, and antiviral drugs. Symptoms include decreased urine output, edema, and increased creatinine and BUN levels. Treatment involves discontinuing the offending drug, maintaining hydration, and renal replacement therapy for severe cases.
In this presentation i have tried to thoroughly discuss about the concept of Drug induced kidney disease or injury, the mechanism behind it, its classification and how to access it.
Drug induced pulmonary diseases can affect the lungs in several ways such as causing bronchospasm, pulmonary edema, pulmonary hypertension, and various types of interstitial lung disease. Common culprit drugs include antibiotics, chemotherapy agents, cardiovascular drugs, NSAIDs, and illicit drugs. Management involves withdrawal of the causative agent, supplemental oxygen, diuretics, corticosteroids, and occasionally immunosuppressants depending on the type and severity of lung disease. Amiodarone is a known cause of delayed pulmonary toxicity that often requires long term corticosteroid treatment.
This document discusses drug-induced acute kidney injury (AKI). It notes that AKI is characterized by an abrupt reduction in kidney function over 48 hours, shown by decreased urine output and increased creatinine levels. Between 5-20% of AKI cases are caused by medications, as kidneys excrete many water-soluble drugs and metabolites. Common culprits include contrast media, ACE inhibitors, NSAIDs, diuretics, and ARBs. Other "red flag" drugs mentioned are aminoglycosides, anticoagulants, anticonvulsants, antivirals, digoxin, immunosuppressants, and hypoglycemic medicines. Treatment focuses on supportive care like fluid management
Slides includes the introduction to drug induced renal disease, pathogenic mechanism by which drug acts on kidney, list of drugs and risk factors.
pathogenic mechanism like altered Interglomerular, Rhabdomyolysis, tubular toxicity, etc.
This presentation discusses drug-induced nephrotoxicity. It defines nephrotoxicity as toxicity in the kidneys caused by toxic chemicals and medications. It identifies several risk factors for drug-induced nephrotoxicity including patient factors like age and pre-existing kidney disease, as well as drug-related factors like dose and interactions. Common clinical signs include decreased urine output and kidney function. Many drugs cause nephrotoxicity through tubular cell toxicity, rhabdomyolysis, or altered blood flow in the kidneys. General measures to prevent nephrotoxicity include adjusting drug dosages, avoiding toxic combinations, ensuring hydration, and using alternative non-nephrotoxic drugs when possible.
The document discusses Drug Induced Kidney Disease (DIKD), specifically drug induced nephrotoxicity. It notes that DIKD is a common complication of various therapeutic agents that can cause abnormalities in acid-base balance, electrolytes, urine sediment, decline in glomerular filtration rate, and increased creatinine and BUN. It identifies several classes of drugs that commonly cause nephrotoxicity like aminoglycosides, amphotericin B, and cisplatin. It also discusses risk factors, clinical presentation, prevention, and various pathological mechanisms of nephrotoxicity including tubular epithelial cell damage, acute tubular necrosis, osmotic nephrosis, and hemodynamically mediated kidney
Renal dialysis is a process that artificially performs the functions of the kidneys for patients with kidney failure. There are two primary types of dialysis - hemodialysis, which uses an external dialysis machine to filter blood outside the body, and peritoneal dialysis, which uses the peritoneal membrane in the abdomen as a filter. Dialysis removes waste and regulates fluid and electrolyte levels by processes of diffusion, ultrafiltration, and osmosis across a semi-permeable membrane. Dialysis is a life-sustaining treatment for end-stage kidney disease.
Drug induced kidney disease (DIKD) is caused by drugs and characterized by increased serum creatinine and blood urea nitrogen levels that are temporally related to drug exposure. Acute tubular necrosis is the most common cause of DIKD in hospitalized patients. Risk factors include increased age, pre-existing kidney disease, use of multiple nephrotoxic drugs, and critical illness. Common culprit drugs are aminoglycosides, radiographic contrast media, nonsteroidal anti-inflammatory drugs, and antiviral drugs. Symptoms include decreased urine output, edema, and increased creatinine and BUN levels. Treatment involves discontinuing the offending drug, maintaining hydration, and renal replacement therapy for severe cases.
In this presentation i have tried to thoroughly discuss about the concept of Drug induced kidney disease or injury, the mechanism behind it, its classification and how to access it.
Drug induced pulmonary diseases can affect the lungs in several ways such as causing bronchospasm, pulmonary edema, pulmonary hypertension, and various types of interstitial lung disease. Common culprit drugs include antibiotics, chemotherapy agents, cardiovascular drugs, NSAIDs, and illicit drugs. Management involves withdrawal of the causative agent, supplemental oxygen, diuretics, corticosteroids, and occasionally immunosuppressants depending on the type and severity of lung disease. Amiodarone is a known cause of delayed pulmonary toxicity that often requires long term corticosteroid treatment.
This document discusses drug-induced acute kidney injury (AKI). It notes that AKI is characterized by an abrupt reduction in kidney function over 48 hours, shown by decreased urine output and increased creatinine levels. Between 5-20% of AKI cases are caused by medications, as kidneys excrete many water-soluble drugs and metabolites. Common culprits include contrast media, ACE inhibitors, NSAIDs, diuretics, and ARBs. Other "red flag" drugs mentioned are aminoglycosides, anticoagulants, anticonvulsants, antivirals, digoxin, immunosuppressants, and hypoglycemic medicines. Treatment focuses on supportive care like fluid management
Slides includes the introduction to drug induced renal disease, pathogenic mechanism by which drug acts on kidney, list of drugs and risk factors.
pathogenic mechanism like altered Interglomerular, Rhabdomyolysis, tubular toxicity, etc.
The document discusses vaccination in patients with chronic kidney disease (CKD). It outlines the rationale and recommendations for vaccination in CKD patients, including those undergoing dialysis or renal transplantation. Specific recommendations are provided for pneumococcal vaccination in CKD patients based on guidelines. The summary discusses how CKD and end-stage renal disease can impair immune function, making vaccinations less effective, and the importance of vaccinating CKD patients to prevent infectious diseases.
This document discusses various drugs and toxins that can affect the kidneys. It begins by introducing the structure and function of the kidneys and nephrons. It then examines different types of kidney injury and failure caused by therapeutic agents, including acute renal failure (pre-renal, intrarenal, postrenal), chronic kidney disease, and nephrotic syndrome. Specific drugs that can cause these conditions are identified, such as NSAIDs, amphotericin B, aminoglycosides, and others. The document focuses on the mechanisms of kidney toxicity for several drugs.
This document discusses various extracorporeal methods for removing drugs from the body, including dialysis, hemoperfusion, and hemofiltration. It provides details on hemodialysis, peritoneal dialysis, continuous ambulatory peritoneal dialysis, hemoperfusion, hemofiltration, and continuous renal replacement therapy. The objective of these extracorporeal removal methods is to rapidly remove undesirable drugs and metabolites from the body without disturbing fluid and electrolyte balance.
This document provides information on the management of peptic ulcer disease. It discusses the physiology of gastric acid secretion, introduces peptic ulcer disease, and outlines various drugs used to treat PUD. Key drugs mentioned include proton pump inhibitors like omeprazole, H2 receptor antagonists like ranitidine, prostaglandin analogues like misoprostol, antacids, and combinations used to eradicate Helicobacter pylori.
This document discusses the pharmacotherapy of malaria. It begins by describing the life cycle and species of the Plasmodium parasite that causes malaria. It then outlines who is most at risk of malaria and the clinical classification of uncomplicated and severe malaria. The major sections cover antimalarial drug classes, treatment guidelines for uncomplicated and severe malaria caused by different parasite species, and prevention through insecticide-treated bed nets, repellents and chemoprophylaxis in travelers.
Tauhid Ahmed Bhuiyan, PharmD presented a document on drug-induced acute kidney injury. The document discussed the background, epidemiology and overview of acute kidney injury. It reviewed the pathogenic mechanisms and prevention strategies of drug-induced acute kidney injury. It also evaluated the implications of computerized clinical decision support systems for medication dosing in patients with renal insufficiency.
This document provides information about the calcium channel blocker amlodipine. It begins with an introduction to calcium channel blockers and their classification. It then focuses on amlodipine, describing its method of synthesis, mechanism of action, and side effects. Amlodipine works by blocking calcium ion entry into vascular smooth muscle and cardiac muscle, relaxing blood vessels to improve blood flow and reduce blood pressure. Potential side effects include swelling, dizziness, nausea, and lightheadedness.
- Older patients are more likely to have multiple chronic illnesses and physiological changes, putting them at higher risk for adverse drug reactions from polypharmacy.
- When prescribing for older patients, doctors should carefully assess whether symptoms are due to normal aging or treatable illness. They should also balance the potential benefits and harms of medications and regularly review if medications are still necessary.
- Doctors are advised to consider dosage forms that are easier for older patients to take correctly, avoid prescribing to treat normal aging, and be aware of potential drug-drug interactions from prescription and over-the-counter medications.
Acte kidney injury-advances in diagnosis & management.Suneth Weerarathna
This document discusses advances in the diagnosis and management of acute kidney injury (AKI). It begins with objectives and outlines of topics including AKI definitions, classification systems, biomarkers for early detection, and management strategies. Novel biomarkers such as Kim-1, NGAL, and cystatin C allow detection of AKI earlier than serum creatinine. While renal replacement therapy is important for established AKI, prevention and treatment of underlying causes are priorities. Overall, awareness of AKI is increasing worldwide and standardized criteria along with new diagnostics and therapies can lead to better outcomes.
These slides were used for discussion in B. Pharmacy 2nd year Pharmacotherapy theory class. Students are suggested to refer textbooks for further information.
Renal dialysis is a process that substitutes many of the normal functions of the kidneys when they are no longer functioning properly. There are two main types of renal dialysis: hemodialysis and peritoneal dialysis. Hemodialysis uses an artificial kidney machine to remove waste, salts, and excess fluid from the blood, while peritoneal dialysis uses the lining of the abdomen to filter blood. Both aim to maintain electrolyte balance and remove toxins from the body until a kidney transplant can be performed or renal function improves. Common complications of renal dialysis include hypotension, muscle cramps, and infections at access sites.
Drug induced dermal disorders ppt by Salva SafdarPARUL UNIVERSITY
The skin is the largest organ in the body, and adverse skin reactions due to drug exposure are a common problem.
The exact mechanism for many of the drug-induced skin diseases is not fully understood and may result from both immune and non-immune mechanisms.
This document discusses drug dosing considerations in renal failure. It notes that dosage refers to the prescribed administration of a drug over time, while dose refers to a single amount. Patients with renal disease are more vulnerable to drug effects, which may increase or decrease. Assessment of renal function includes serum creatinine and BUN levels. Estimating glomerular filtration rate (eGFR) accounts for average body size. Many drugs require dosage adjustments or alternative choices in renal failure, especially those excreted renally. Loading doses do not typically change, while maintenance doses depend on drug clearance. Some antibiotics do not require adjustment.
The document discusses the resurgence of the antibiotic fosfomycin for treating infections caused by drug-resistant bacteria. It notes the increasing problems of antibiotic resistance have created a need to re-evaluate existing treatment options. Fosfomycin has a unique mechanism of action and activity against both gram-positive and gram-negative bacteria. It has demonstrated efficacy against common infections like UTIs and is particularly useful in combination with other antibiotics for multi-drug resistant infections in critical care settings.
This document provides an overview of diuretics for medical students. It begins by classifying diuretics into high ceiling, medium efficacy, and weak categories. It then focuses on the mechanisms and effects of loop diuretics like furosemide and thiazide diuretics. Loop diuretics work by inhibiting sodium-potassium-chloride transport in the thick ascending limb, while thiazides inhibit sodium-chloride transport in the distal tubule. The document compares the adverse effects and drug interactions of these classes. It concludes by emphasizing how diuretics are commonly used to treat hypertension and edema and can interact with other drugs.
This document summarizes HIV infection and treatment. It describes how HIV was identified in the 1980s as the cause of AIDS. HIV can be transmitted through bodily fluids. Left untreated, HIV weakens the immune system and allows opportunistic infections. Treatment aims to suppress the virus and restore immune function. Highly Active Antiretroviral Therapy (HAART) uses a combination of three antiretroviral drugs from two classes to control the virus. Guidelines recommend starting treatment based on CD4 count. The goals of treatment are to improve quality of life and prevent disease progression.
This document discusses nephrotoxic drugs and their impact on kidney function. It begins by explaining how renal damage from drugs can cause significant health issues like acute kidney injury and chronic kidney disease, as well as increasing medical costs. It then identifies several common classes of drugs that can cause nephrotoxicity, such as antibiotics, chemotherapy agents, antihypertensives, and NSAIDs. The document discusses mechanisms of nephrotoxicity for different drug classes and regions of the kidney. It also examines renal biomarkers that can help identify kidney injury earlier than serum creatinine. Finally, it provides examples of renal protective strategies like dose adjustments, monitoring, and hydration that can reduce the nephrotoxic risks of certain
This document discusses extracorporeal therapies and renal replacement therapy (RRT). It describes different types of RRT including intermittent hemodialysis, continuous dialysis, and their principles and setup. It covers non-renal uses of RRT such as for sepsis, acute respiratory distress syndrome, congestive heart failure, and more. It also describes hemoperfusion, which uses activated charcoal or resin to adsorb molecules from blood, and issues around preventing clotting during the process.
Pharmacokinetic changes in renal impairment and dosage considerationsDr Htet
The kidneys play a key role in drug elimination from the body. Renal impairment can affect the pharmacokinetics of many drugs by reducing their excretion, increasing their bioavailability and toxicity. Dosage regimens must be adapted based on a patient's level of renal function and whether the drug or its metabolites are renally excreted. Drugs that are nephrotoxic or have a narrow therapeutic index require especially close monitoring and dosage adjustment according to glomerular filtration rate in patients with renal impairment.
The document discusses the pharmacotherapy of HIV/AIDS, including:
- Classification of antiretroviral drugs into NRTIs, NNRTIs, PIs, entry inhibitors, integrase inhibitors, and maturation inhibitors.
- Guidelines for starting antiretroviral therapy (ART) and recommendations for first and second line regimens.
- "Off label" uses of drugs like azithromycin, foscarnet, and hydroxyurea to treat opportunistic infections in HIV patients.
Detailed mechanisms of certain antimicrobials that cause renal failure
ANTIMICROBIALS CAUSING RENAL FAILURE
Aminoglycosides
Amphotericin – B
Trimethoprim
B – lactam antibiotics
Fluoroquinolones
Vancomycin
Acyclovir
Tetracycline
Many medicines can cause acute kidney injury (which used to be called acute renal failure), such as:
Antibiotics. These include aminoglycosides, cephalosporins, amphotericin B, bacitracin, and vancomycin.
Antihypertensive: ACE inhibitors, such as lisinopril and ramipril; Angiotensin receptor blockers, such as candesartan and valsartan.
Anticancer drugs (chemotherapy): Examples are cisplatin, carboplatin, and methotrexate.
Dyes (contrast media):These are used in medical imaging tests.
Illegal drugs: Examples are heroin and methamphetamine.
Antiviral drugs: Examples are indinavir and ritonavir, acyclovir
Non-steroidal anti-inflammatory drugs: These include ibuprofen, ketoprofen, and naproxen.
Anti Ulcer medicines: One example is cimetidine.
Drug-induced kidney disease or nephrotoxicity (DIN) is a relatively common complication of several diagnostic and therapeutic agents.
Any drug in the blood will eventually reach the highly vascularized kidneys
It may potentially cause drug induced renal failure
If the drug is primarily cleared by the kidney, the drug will become increasingly concentrated as it moves from the renal artery into the smaller vasculature of the kidney
The drug may be filtered or secreted into the lumen of the renal tubules
The concentrated drug exposes the kidney tissue to far greater drug concentration per surface area
The document discusses vaccination in patients with chronic kidney disease (CKD). It outlines the rationale and recommendations for vaccination in CKD patients, including those undergoing dialysis or renal transplantation. Specific recommendations are provided for pneumococcal vaccination in CKD patients based on guidelines. The summary discusses how CKD and end-stage renal disease can impair immune function, making vaccinations less effective, and the importance of vaccinating CKD patients to prevent infectious diseases.
This document discusses various drugs and toxins that can affect the kidneys. It begins by introducing the structure and function of the kidneys and nephrons. It then examines different types of kidney injury and failure caused by therapeutic agents, including acute renal failure (pre-renal, intrarenal, postrenal), chronic kidney disease, and nephrotic syndrome. Specific drugs that can cause these conditions are identified, such as NSAIDs, amphotericin B, aminoglycosides, and others. The document focuses on the mechanisms of kidney toxicity for several drugs.
This document discusses various extracorporeal methods for removing drugs from the body, including dialysis, hemoperfusion, and hemofiltration. It provides details on hemodialysis, peritoneal dialysis, continuous ambulatory peritoneal dialysis, hemoperfusion, hemofiltration, and continuous renal replacement therapy. The objective of these extracorporeal removal methods is to rapidly remove undesirable drugs and metabolites from the body without disturbing fluid and electrolyte balance.
This document provides information on the management of peptic ulcer disease. It discusses the physiology of gastric acid secretion, introduces peptic ulcer disease, and outlines various drugs used to treat PUD. Key drugs mentioned include proton pump inhibitors like omeprazole, H2 receptor antagonists like ranitidine, prostaglandin analogues like misoprostol, antacids, and combinations used to eradicate Helicobacter pylori.
This document discusses the pharmacotherapy of malaria. It begins by describing the life cycle and species of the Plasmodium parasite that causes malaria. It then outlines who is most at risk of malaria and the clinical classification of uncomplicated and severe malaria. The major sections cover antimalarial drug classes, treatment guidelines for uncomplicated and severe malaria caused by different parasite species, and prevention through insecticide-treated bed nets, repellents and chemoprophylaxis in travelers.
Tauhid Ahmed Bhuiyan, PharmD presented a document on drug-induced acute kidney injury. The document discussed the background, epidemiology and overview of acute kidney injury. It reviewed the pathogenic mechanisms and prevention strategies of drug-induced acute kidney injury. It also evaluated the implications of computerized clinical decision support systems for medication dosing in patients with renal insufficiency.
This document provides information about the calcium channel blocker amlodipine. It begins with an introduction to calcium channel blockers and their classification. It then focuses on amlodipine, describing its method of synthesis, mechanism of action, and side effects. Amlodipine works by blocking calcium ion entry into vascular smooth muscle and cardiac muscle, relaxing blood vessels to improve blood flow and reduce blood pressure. Potential side effects include swelling, dizziness, nausea, and lightheadedness.
- Older patients are more likely to have multiple chronic illnesses and physiological changes, putting them at higher risk for adverse drug reactions from polypharmacy.
- When prescribing for older patients, doctors should carefully assess whether symptoms are due to normal aging or treatable illness. They should also balance the potential benefits and harms of medications and regularly review if medications are still necessary.
- Doctors are advised to consider dosage forms that are easier for older patients to take correctly, avoid prescribing to treat normal aging, and be aware of potential drug-drug interactions from prescription and over-the-counter medications.
Acte kidney injury-advances in diagnosis & management.Suneth Weerarathna
This document discusses advances in the diagnosis and management of acute kidney injury (AKI). It begins with objectives and outlines of topics including AKI definitions, classification systems, biomarkers for early detection, and management strategies. Novel biomarkers such as Kim-1, NGAL, and cystatin C allow detection of AKI earlier than serum creatinine. While renal replacement therapy is important for established AKI, prevention and treatment of underlying causes are priorities. Overall, awareness of AKI is increasing worldwide and standardized criteria along with new diagnostics and therapies can lead to better outcomes.
These slides were used for discussion in B. Pharmacy 2nd year Pharmacotherapy theory class. Students are suggested to refer textbooks for further information.
Renal dialysis is a process that substitutes many of the normal functions of the kidneys when they are no longer functioning properly. There are two main types of renal dialysis: hemodialysis and peritoneal dialysis. Hemodialysis uses an artificial kidney machine to remove waste, salts, and excess fluid from the blood, while peritoneal dialysis uses the lining of the abdomen to filter blood. Both aim to maintain electrolyte balance and remove toxins from the body until a kidney transplant can be performed or renal function improves. Common complications of renal dialysis include hypotension, muscle cramps, and infections at access sites.
Drug induced dermal disorders ppt by Salva SafdarPARUL UNIVERSITY
The skin is the largest organ in the body, and adverse skin reactions due to drug exposure are a common problem.
The exact mechanism for many of the drug-induced skin diseases is not fully understood and may result from both immune and non-immune mechanisms.
This document discusses drug dosing considerations in renal failure. It notes that dosage refers to the prescribed administration of a drug over time, while dose refers to a single amount. Patients with renal disease are more vulnerable to drug effects, which may increase or decrease. Assessment of renal function includes serum creatinine and BUN levels. Estimating glomerular filtration rate (eGFR) accounts for average body size. Many drugs require dosage adjustments or alternative choices in renal failure, especially those excreted renally. Loading doses do not typically change, while maintenance doses depend on drug clearance. Some antibiotics do not require adjustment.
The document discusses the resurgence of the antibiotic fosfomycin for treating infections caused by drug-resistant bacteria. It notes the increasing problems of antibiotic resistance have created a need to re-evaluate existing treatment options. Fosfomycin has a unique mechanism of action and activity against both gram-positive and gram-negative bacteria. It has demonstrated efficacy against common infections like UTIs and is particularly useful in combination with other antibiotics for multi-drug resistant infections in critical care settings.
This document provides an overview of diuretics for medical students. It begins by classifying diuretics into high ceiling, medium efficacy, and weak categories. It then focuses on the mechanisms and effects of loop diuretics like furosemide and thiazide diuretics. Loop diuretics work by inhibiting sodium-potassium-chloride transport in the thick ascending limb, while thiazides inhibit sodium-chloride transport in the distal tubule. The document compares the adverse effects and drug interactions of these classes. It concludes by emphasizing how diuretics are commonly used to treat hypertension and edema and can interact with other drugs.
This document summarizes HIV infection and treatment. It describes how HIV was identified in the 1980s as the cause of AIDS. HIV can be transmitted through bodily fluids. Left untreated, HIV weakens the immune system and allows opportunistic infections. Treatment aims to suppress the virus and restore immune function. Highly Active Antiretroviral Therapy (HAART) uses a combination of three antiretroviral drugs from two classes to control the virus. Guidelines recommend starting treatment based on CD4 count. The goals of treatment are to improve quality of life and prevent disease progression.
This document discusses nephrotoxic drugs and their impact on kidney function. It begins by explaining how renal damage from drugs can cause significant health issues like acute kidney injury and chronic kidney disease, as well as increasing medical costs. It then identifies several common classes of drugs that can cause nephrotoxicity, such as antibiotics, chemotherapy agents, antihypertensives, and NSAIDs. The document discusses mechanisms of nephrotoxicity for different drug classes and regions of the kidney. It also examines renal biomarkers that can help identify kidney injury earlier than serum creatinine. Finally, it provides examples of renal protective strategies like dose adjustments, monitoring, and hydration that can reduce the nephrotoxic risks of certain
This document discusses extracorporeal therapies and renal replacement therapy (RRT). It describes different types of RRT including intermittent hemodialysis, continuous dialysis, and their principles and setup. It covers non-renal uses of RRT such as for sepsis, acute respiratory distress syndrome, congestive heart failure, and more. It also describes hemoperfusion, which uses activated charcoal or resin to adsorb molecules from blood, and issues around preventing clotting during the process.
Pharmacokinetic changes in renal impairment and dosage considerationsDr Htet
The kidneys play a key role in drug elimination from the body. Renal impairment can affect the pharmacokinetics of many drugs by reducing their excretion, increasing their bioavailability and toxicity. Dosage regimens must be adapted based on a patient's level of renal function and whether the drug or its metabolites are renally excreted. Drugs that are nephrotoxic or have a narrow therapeutic index require especially close monitoring and dosage adjustment according to glomerular filtration rate in patients with renal impairment.
The document discusses the pharmacotherapy of HIV/AIDS, including:
- Classification of antiretroviral drugs into NRTIs, NNRTIs, PIs, entry inhibitors, integrase inhibitors, and maturation inhibitors.
- Guidelines for starting antiretroviral therapy (ART) and recommendations for first and second line regimens.
- "Off label" uses of drugs like azithromycin, foscarnet, and hydroxyurea to treat opportunistic infections in HIV patients.
Detailed mechanisms of certain antimicrobials that cause renal failure
ANTIMICROBIALS CAUSING RENAL FAILURE
Aminoglycosides
Amphotericin – B
Trimethoprim
B – lactam antibiotics
Fluoroquinolones
Vancomycin
Acyclovir
Tetracycline
Many medicines can cause acute kidney injury (which used to be called acute renal failure), such as:
Antibiotics. These include aminoglycosides, cephalosporins, amphotericin B, bacitracin, and vancomycin.
Antihypertensive: ACE inhibitors, such as lisinopril and ramipril; Angiotensin receptor blockers, such as candesartan and valsartan.
Anticancer drugs (chemotherapy): Examples are cisplatin, carboplatin, and methotrexate.
Dyes (contrast media):These are used in medical imaging tests.
Illegal drugs: Examples are heroin and methamphetamine.
Antiviral drugs: Examples are indinavir and ritonavir, acyclovir
Non-steroidal anti-inflammatory drugs: These include ibuprofen, ketoprofen, and naproxen.
Anti Ulcer medicines: One example is cimetidine.
Drug-induced kidney disease or nephrotoxicity (DIN) is a relatively common complication of several diagnostic and therapeutic agents.
Any drug in the blood will eventually reach the highly vascularized kidneys
It may potentially cause drug induced renal failure
If the drug is primarily cleared by the kidney, the drug will become increasingly concentrated as it moves from the renal artery into the smaller vasculature of the kidney
The drug may be filtered or secreted into the lumen of the renal tubules
The concentrated drug exposes the kidney tissue to far greater drug concentration per surface area
This document discusses xenobiotic effects on the kidney. It provides an overview of kidney anatomy and function, specifically its role in filtering and excreting wastes and toxins. Various nephrotoxicants like heavy metals, therapeutic agents, and contrast dyes are described. Mercury, cadmium, NSAIDs, aminoglycosides, cisplatin, and radiocontrast agents can damage the glomeruli, proximal tubules, or cause acute or chronic injury. Concentration of toxins in renal filtrate and metabolism within tubular cells increases kidney susceptibility. Specific mechanisms of nephrotoxicity are outlined for different substances.
This document discusses various medication-induced kidney injuries. It covers:
1. Risk factors for drug nephrotoxicity including patient factors like age, sex, CKD/AKI status.
2. Pathophysiology of drug nephrotoxicity including how single drugs can affect different kidney sites and how multiple drugs can affect the same site.
3. Classification of drug-induced kidney injury including prerenal AKI, acute tubular necrosis, acute/chronic interstitial nephritis, glomerular disease, and obstructive nephropathy.
4. Specific nephrotoxic drugs that can cause the different types of injury through various mechanisms are discussed along with
This document discusses how drugs are eliminated by the kidneys and the mechanisms of renal injury caused by various drugs. It notes that many drugs can injure the kidneys through a few common mechanisms, such as altering renal blood flow or causing direct tubular toxicity. It provides examples of specific drugs that can cause these types of renal injuries. The document also discusses factors that influence drug dosing in patients with renal impairment and principles for safely prescribing drugs in such patients.
Brief Review Of Chemotherapeutic Agents And Renal Failureguest6940925
The document provides an overview of chemotherapeutic agents that can cause renal failure. Several classes of chemotherapy drugs like cisplatin, carboplatin, cyclophosphamide, ifosfamide, and nitrosoureas are discussed in terms of their mechanisms of nephrotoxicity and clinical manifestations. Strategies for prevention and management of renal toxicity from chemotherapy are also briefly reviewed.
Molecular mechanism of drug induced nephrotoxicitySuman Manandhar
This document discusses nephrotoxicity, or kidney damage, caused by drugs. It provides an introduction and overview of types of nephrotoxicity and biomarkers for detecting drug-induced renal damage. It then discusses several common pathogenic mechanisms by which drugs can cause nephrotoxicity, including altered intraglomerular hemodynamics, tubular cell toxicity, inflammation, crystal nephropathy, rhabdomyolysis, and thrombotic microangiopathy. Specific examples are given of how certain drugs like aminoglycosides, cyclosporine, and cisplatin can cause nephrotoxicity through these mechanisms.
Drug-induced kidney disease (DIKD) can have various presentations depending on the drug and clinical setting. Studies show that 20-30% of hospital-acquired acute kidney injury (AKI) cases are associated with nephrotoxic medications such as aminoglycosides, iodinated contrast media, and NSAIDs. DIKD most commonly manifests as acute tubular necrosis, characterized by rises in serum creatinine and BUN, along with urinary abnormalities. Prevention focuses on avoiding unnecessary nephrotoxic drugs, proper dosing based on kidney function, and adequate hydration. Management involves discontinuing causative agents and providing supportive care.
Nephrotoxic drugs can damage the kidneys by several mechanisms. Certain patient characteristics like older age, pre-existing kidney disease, and volume depletion increase risk. Common nephrotoxic drug classes include antibiotics, chemotherapy drugs, antivirals, NSAIDs, and statins. Drugs may cause acute kidney injury through effects on hemodynamics, tubular toxicity, inflammation, crystal formation, or rhabdomyolysis. Early recognition of rising creatinine and discontinuing the offending drug is important to reverse damage. Preventing nephrotoxicity requires assessing risks, monitoring for injury, and avoiding unnecessary nephrotoxic medications.
This document discusses antigout drugs used to treat gout. It begins by defining gout as a metabolic disease caused by increased uric acid levels in the blood. It then describes the mechanisms and classifications of various antigout drugs including allopurinol, probenecid, sulfinpyrazone, corticosteroids, NSAIDs, and colchicine. For each drug, it discusses their mechanisms of action, pharmacokinetics, uses, interactions, toxicity, and administration guidelines for treating both acute and chronic gout. The document provides an in-depth overview of different drug classes used to manage hyperuricemia and gouty arthritis.
The number of drugs associated with adverse reactions involving the liver is extensive, but in clinical practice is dominated by alcohol, antibiotics, antiepileptic medications and acetaminophen.
Complementary (herbal) medicines contribute to Liver Dysfuntion.
This document discusses how various diseases can affect drug pharmacokinetics and metabolism. It covers effects of gastrointestinal, cardiac, renal, liver and thyroid disorders. Key points include:
- Renal and liver diseases can significantly impact drug absorption, distribution, metabolism and excretion. Dose adjustments are often needed.
- Cardiac failure can alter drug distribution and decrease elimination due to reduced hepatic and renal perfusion.
- Monitoring drug levels can help optimize therapy for individual patients, especially when inter-individual variability is high or clinical effects are difficult to assess. Close monitoring of response is important when prescribing for patients with organ dysfunction.
Brief Review Of Chemotherapeutic Agents And Renal FailureTejas Desai
Chemotherapeutic agents can cause nephrotoxicity through various mechanisms like direct tubular injury, vascular damage or glomerular effects. Cisplatin is one of the most nephrotoxic agents causing proximal tubule injury and electrolyte wasting. Carboplatin is safer but can still cause renal failure. VEGF inhibitors commonly cause proteinuria and hypertension. Nitrosoureas can lead to chronic interstitial nephritis. Methotrexate nephrotoxicity is exacerbated by dehydration. Gemcitabine and mitomycin C are associated with renal failure and HUS, sometimes months after the last dose. Early detection and prevention are key to managing chemotherapy-induced renal injury.
Anti-Rhumatics in Renal and Liver impairmentRehab Rayan
The document outlines the contributions of team members to a project on disease-modifying antirheumatic drugs (DMARDs) used to treat rheumatoid arthritis. It assigns team members to discuss specific DMARDs and other drug classes. It will cover D-penicillamine, azathioprine, antimalarials, sodium aurothiomalate, corticosteroids, NSAIDs, celecoxib, rituximab, abatacept, TNF-alpha antagonists, and provide a summary. The toxicity profiles, particularly renal and hepatic toxicity, of several DMARDs will be discussed including D-penicillamine, cyclosporine, azathioprine, methotrexate,
1. Acute renal failure is a sudden deterioration of kidney function that results in the build up of waste products in the body. It can be caused by decreased blood flow to the kidneys, direct kidney damage, or urinary tract obstruction.
2. The kidneys normally maintain fluid and electrolyte balance and remove waste. In acute renal failure, the kidneys are unable to perform these functions. This leads to fluid, electrolyte, and acid-base imbalances.
3. Acute renal failure is classified as prerenal, intrarenal, or postrenal depending on the underlying cause. Prerenal causes decrease blood flow, intrarenal causes direct damage, and postrenal causes
The presentation provided an overview of nephrotoxins and their mechanisms of toxicity. It discussed common nephrotoxic drugs like aminoglycosides, cisplatin, and NSAIDs. Heavy metals and certain herbs were also reviewed as nephrotoxins. The presentation assessed knowledge of NSAID nephrotoxicity among drivers, finding most were unaware of risks. It concluded nephrotoxins can injure kidneys through various mechanisms, and pharmacists have an important role in educating patients about risks.
Dr. Sachin Verma is a young, diligent and dynamic physician. He did his graduation from IGMC Shimla and MD in Internal Medicine from GSVM Medical College Kanpur. Then he did his Fellowship in Intensive Care Medicine (FICM) from Apollo Hospital Delhi. He has done fellowship in infectious diseases by Infectious Disease Society of America (IDSA). He has also done FCCS course and is certified Advance Cardiac Life support (ACLS) and Basic Life Support (BLS) provider by American Heart Association. He has also done a course in Cardiology by American College of Cardiology and a course in Diabetology by International Diabetes Centre. He specializes in the management of Infections, Multiorgan Dysfunctions and Critically ill patients and has many publications and presentations in various national conferences under his belt. He is currently working in NABH Approved Ivy super-specialty Hospital Mohali as Consultant Intensivists and Physician.
The respiratory system has three main functions: gas exchange, regulating blood pH, and producing sounds. It consists of the upper respiratory tract including the nose and pharynx, and the lower tract including the lungs. Respiration has three steps: pulmonary ventilation, external respiration of gas exchange in the lungs, and internal respiration of gas exchange in tissues. The lungs obtain oxygen and expel carbon dioxide through breathing which involves the muscles and elastic recoil of the lungs and chest wall. The document then discusses various respiratory structures, processes, and disorders in more detail.
Genetic polymorphisms are variations in gene sequences that occur in at least 1% of the general population, resulting in multiple alleles or variants of a gene sequence.
The most commonly occurring form of genetic variability is the single nucleotide polymorphism (SNP, often called “snip”)
Population pharmacokinetics is the study of the sources and correlates of variability in drug concentrations among individuals who are the target patient population receiving clinically relevant doses of a drug of interest
Clinical pharmacokinetics is the discipline that applies pharmacokinetic concepts and principles in humans in order to design individualized dosage regimens which optimize the therapeutic response of a medication while minimizing the chance of an adverse drug reaction.
Cardiac cycle is defined as the succession of coordinated events taking place in the heart during each beat. Each heart beat consists of two major periods called systole and diastole.
Although some lymphocytes have a lifetime measured in years, most formed elements of the blood last only hours, days, or weeks, and must be replaced continually.
Negative feedback systems regulate the total number of RBCs and platelets in circulation, and their numbers normally remain steady.
The abundance of the different types of WBCs, however, varies in response to challenges by invading pathogens and other foreign antigens.
Advances in migraine therapy pedagogy session 27/11/21PARUL UNIVERSITY
Migraine is a neurological disease that affects 12% of the US population, manifesting as severe headache pain on one side of the head that can last between 4 to 72 hours. It was previously believed to be caused by blood vessel dilation but is now understood to involve sensitization of trigeminal pathways. Stimulation of the trigeminal ganglion leads to the release of substances like CGRP that cause neurogenic inflammation linked to migraine pain. A patient presents with a history of migraine with aura and is frustrated with a lack of success from oral triptans. He is recommended to take triptans earlier in attacks and begin preventive medications or switch to parenteral triptans to improve outcomes.
The heart has four chambers. The two superior receiving chambers are the atria (= entry halls or chambers), and the two inferior pumping chambers are the ventricles (= little bellies).
On the anterior surface of each atrium is a wrinkled pouchlike structure called an auricle
Desmopressin
Lypressin
Terlipressin
Felypressin
Argipressin
ornipressin
Desmopressin: It is a selective V2-receptor agonist and is more potent than vasopressin as an antidiuretic. It has negligible vasoconstrictor action. It is administered by oral, nasal and parenteral routes. Lypressin: It acts on both V1- and V2-receptors. It is less potent but longer acting than vasopressin. It is administered parenterally. Terlipressin: It is a prodrug of vasopressin with selective V1 action. It is administered intravenously. Felypressin: It is a synthetic analogue of vasopressin. It is mainly used for its vasoconstrictor (V1 ) action along with local anaesthetics to prolong the duration of action. Felypressin should be avoided in pregnancy because of its oxytocic (uterine stimulant) activity.
Management of Peripheral Neuropathy and Cardiovascular Effects in Vitamin B1...PARUL UNIVERSITY
Peripheral nerves are susceptible to damage by a wide array of toxins, medications, and vitamin
deficiencies. Vitamin B12 (VB12) deficiency neuropathy is a rare debilitating disease that affects
mostly the elderly. It is important to consider these etiologies when approaching patients with a variety
of neuropathic presentations in this review were have included most relevant and latest information on
mechanisms causing Peripheral neuropathy in VB12 deficiency. We also have included cardiovascular
disorders and their management. Hyperhomocysteinemia has been implicated in endothelial
dysfunction and cardiovascular disease. The association of homocysteine (Hcy) and VB12 with
cardiovascular risk factors in patients with coronary artery disease (CAD) has also been studied
Moyamoya disease (MMD) is a rare and unique cerebrovascular disease. The term “moyamoya” is Japanese and refers to a hazy puff of smoke or cloud. In people with moyamoya disease, this is how the blood vessels appear in the angiogram. MMD is characterized by the progressive stenosis of the distal internal carotid artery (ICA) resulting in a hazy network of basal collaterals called moyamoya vessels. This may be a consequence of Mutations in a few genes. In addition, MMD is also associated with many genetically transmitted disorders, including neurofibromatosis, Down syndrome, Sickle cell anemia, and Collagen vascular disease. It follows bimodal age distribution. Younger populations present with ischaemic symptoms, whereas adults show hemorrhagic symptoms The exact cause remains unknown. Immune, genetic and other factors contribute to this disease. It follows complex pathophysiology resulting in neovascularization as a compensatory mechanism. Diagnosis is based on cerebral angiography using the DSA scale. Treatment involves managing symptoms with medicine or surgery, improving blood flow to the brain, and controlling seizures. Revascularization helps to rebuild the blood supply to the underside of the brain.
A case report on Rheumatoid Arthritis with sickle cell traitPARUL UNIVERSITY
A female patient aged 6 years, a suspected case of sickle cell trait (SCT) having symptoms of Rheumatoid arthritis (RA),
while evaluating joint complaints in adult sickle cell disease (SCD) patients, a number of sickle cell-based entities come
to mind such as avascular necrosis, osteomyelitis, bone infarcts, and septic arthritis. RA is a chronic systemic
inflammatory disease, many reports highlighted the occurrence of RA in SCD presenting as diagnostic challenges for
cases with chronic inflammatory arthritis, SCT also have appeared to persist in some populations at a perplexingly high
rate given the degree of early mortality of homozygosity of SCD, our case report showed that not only SCD but if a patient
has SCT they can develop RA as complication. Our case report concludes that during the evaluation of a SCT patient who
presents with chronic synovitis, one should strongly consider the possibility of coexistence of RA and SCT.
The appendicular skeleton consists of the
shoulder girdle with the upper limbs and the
pelvic girdle with the lower limbs
Shoulder girdle and upper limb:
Each shoulder girdle consists of:
•1 clavicle
•1 scapula.
Each upper limb consists of the following bones:
1 humerus, 1 radius, 1 ulna, 8 carpal bones, 5 metacarpal bones and 14 phalanges.
Histamine is a biogenic amine present in many tissues that functions as a neurotransmitter and is involved in inflammatory and hypersensitivity reactions. It is synthesized from the amino acid histidine. Histamine acts through multiple receptor subtypes and is involved in various physiological processes like gastric acid secretion, smooth muscle contraction, and allergic responses. Antihistamines competitively inhibit histamine receptors, with first generation antihistamines having sedative effects and second generation ones having minimal side effects. They are used to treat allergic disorders, as antiemetics, and for gastric acid reduction with H2 blockers. Concerns have been raised about impurities in the H2 blocker ranitidine. While H3
Anabolic steroids promote protein synthesis and increase muscle mass, resulting in weight gain.
Testosterone is secreted by the testis and is the main androgen in the plasma of men. In women, testosterone (in small amounts) is secreted by the ovary and adrenal glands. Many of the androgens are modified forms of testosterone
Kinetics: Absorbed orally and from of injection site and undergoes rapid first pass metabolism and quick metabolism respectively. In order to retard the rate of absorption, testosterone esters in oil are used which are less polar than the free steroid.
DKA
HHS
CASE DISCUSSION
DIABETES COMPLICATION
Hyperglycaemia is the main cause leading to dehydration due to osmotic diuresis which, if severe, results in hyperosmolarity. In HHS, unlike diabetic ketoacidosis, there is no significant ketone production and therefore no severe acidosis.
Hyperosmolarity may increase blood viscosity and the risk of thromboembolism. Factors precipitating HHS are infection, myocardial infarction, poor adherence with medication regimens or medicines which cause diuresis or impair glucose tolerance, for example, glucocorticoids.
A study on the pharmacological management of mineral bone disease in chronick...PARUL UNIVERSITY
This document summarizes a study on the pharmacological management of mineral bone disease in chronic kidney disease patients. The study included 180 patients with chronic kidney disease divided into groups with and without diabetes mellitus. Key findings include:
1) Serum calcium levels were significantly increased and estimated GFR significantly decreased in all patients at conclusion compared to baseline.
2) Serum calcium levels were significantly higher at conclusion in non-diabetic CKD patients, while estimated GFR decreased significantly in diabetic CKD patients.
3) The proportion of untreated patients was high for all drugs except vitamin D analogues in both CKD subgroups.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
1. ANTIMICROBIAL INDUCED RENAL FAILURE
PRESENTED BY:
Dr.SHAISTA SUMAYYA
PHARMD, DEPT. OF PHARMACY PRACTICE
SULTAN UL ULOOM COLLEGE OF PHARMACY,
HYDERABAD
GUIDED BY:
Dr. S.P
.SRINIVAS NAYAK
ASSISTANT PROFESSOR, SUCP
1
2. INTRODUCTION
The kidney maintains the vital functions of clearing excess body fluid and removing
metabolic and exogenous toxins from the blood
The kidney is particularly vulnerable to drugs and other agents that cause renal damage
The heart pumps approximately 25% of cardiac output into the kidneys
Any drug in the blood will eventually reach the highly vascularized kidneys
It may potentially cause drug induced renal failure
If the drug is primarily cleared by the kidney, the drug will become increasingly concentrated
as it moves from the renal artery into the smaller vasculature of the kidney
The drug may be filtered or secreted into the lumen of the renal tubules
The concentrated drug exposes the kidney tissue to far greater drug concentration per
surface area
Drug-induced kidney disease or nephrotoxicity (DIN) is a relatively common complication of
several diagnostic and therapeutic agents.
2
3. CLINICAL PRESENTATION
GENERAL
• Decline in GFR leading to
rise in Scr and BUN
• Malaise, anorexia, SOB,
oedema, vomiting
SIGNS
• Decreased urine output
• Proximal tubular injury:
Metabolic acidosis,
glycosuria, reduction in
serum phosphate, uric acid,
K, Mg
• Distal tubular injury:
Polyuria, metabolic acidosis,
hyperkalaemia
DIAGNOSTIC TESTS
• Proximal tubular injury
markers: Gamma glutamyl
transpeptidase, glutathione
S transferase, interleukin –
18
• Kidney injury molecule –
1: Expressed in proximal
tubular injury and
upregulated in ischemic
acute tubular necrosis –
appears within 12 hrs.
• Neutrophil gelatinase
associated lipocalin:
protein detected in urine
within 3hrs of ischemic injury
3
5. DRUGS CAUSING ACUTE RENAL FAILURE
Many medicines can cause acute kidney injury (which used to be called acute renal failure), such
as:
Antibiotics. These include aminoglycosides, cephalosporins, amphotericin B, bacitracin, and
vancomycin.
Antihypertensive: ACE inhibitors, such as lisinopril and ramipril; Angiotensin receptor blockers,
such as candesartan and valsartan.
Anticancer drugs (chemotherapy): Examples are cisplatin, carboplatin, and methotrexate.
Dyes (contrast media):These are used in medical imaging tests.
Illegal drugs: Examples are heroin and methamphetamine.
Antiviral drugs: Examples are indinavir and ritonavir, acyclovir
Non-steroidal anti-inflammatory drugs: These include ibuprofen, ketoprofen, and naproxen.
Anti Ulcer medicines: One example is cimetidine.
5
8. Aminoglycoside Nephrotoxicity
Pathogenesis:
Aminoglycosides are believed to cause nephrotoxicity via Tubular epithelial cell
damage i.e. acute tubular necrosis
The reduction of GFR in patients receiving aminoglycosides is predominantly the
result of proximal tubular epithelial cell damage leading to obstruction of the tubular
lumen and back leakage of the glomerular filtrate across the damaged tubular
epithelium.
Toxicity may be related to cationic charge, which facilitates binding of filtered
aminoglycosides to renal tubular epithelial cell luminal membranes, followed by
intracellular transport and concentration in lysosomes.
8
9. Cellular dysfunction and death may result from release of lysosomal enzymes
into the cytosol, generation of reactive oxygen species, altered cellular
metabolism, and alterations in cell membrane fluidity, leading to reduced
activity of membrane-bound enzymes, including Na+-K+- ATPase, dipeptidyl
peptidase IV, and neutral amino peptidase.
Aminoglycosides preferentially affect the proximal tubular cells.
These agents are freely filtered by the glomeruli and quickly taken up by the
proximal tubular epithelial cells, where they are incorporated into lysosomes
after first interacting with phospholipids on the brush border membranes.
They exert their main toxic effect within the tubular cell by altering
phospholipid metabolism.
In addition to their direct effect on cells, aminoglycosides cause renal
vasoconstriction.
9
10. Approximately 5% of the administered dose accumulates within epithelial
cells after glomerular filtration
Aminoglycoside uptake by the tubules is a saturable phenomenon, so
uptake is limited after a single dose.
Thus, a single daily large dose is preferable to 3 doses per day.
Aminoglycosides have molecular weight of approximately 500 Dalton and
are water-soluble and minimally protein bound.
The primary route of elimination from the body is glomerular filtration,
which is nearly equal to inulin clearance.
The serum half-life of aminoglycosides is a few hours as compared to 4 to
5 days in proximal tubule cells.
10
12. RISK FACTORS
Increased risk
Fluid depletion
Potassium and magnesium deficiency
Endotoxaemia
Pre-existing renal disease
Advanced age
Co-administration of other nephrotoxins
Lengthy duration of treatment
Repeated courses of aminoglycosides
Liver disease
Obesity/male sex
Decreased risk
Organic polycations
Urinary alkalinisation
Thyroid hormone
Potassium loading
12
13. PREVENTION
Use of alternative antibiotics - fluoroquinolones (e.g., ciprofloxacin or levofloxacin) and
third- or fourth-generation cephalosporins (e.g., ceftazidime or cefepime)
When aminoglycosides are necessary, the specific drug used does not appear to
significantly affect the risk of nephrotoxicity, and therapy should be selected to optimize
antimicrobial efficacy
Avoid volume depletion
Limit the total aminoglycoside dose administered
Avoid concomitant therapy with other nephrotoxic drugs
once-daily dosing. (Although greater clinical efficacy and reduced nephrotoxicity may be
realized with once-daily compared to standard dosing, seriously ill, immunocompromised,
and elderly patients, as well as patients with preexisting kidney disease, are not ideal
candidates for this approach because of altered aminoglycoside clearance in these
patients).
13
14. AMPHOTERICIN B NEPHROTOXICITY
Amphotericin B remains the anti-fungal drug of choice for most systemic infections, but a
limiting factor for its use is the development of nephrotoxicity.
Amphotericin B is believed to cause nephrotoxicity via Tubular epithelial cell damage i.e.
acute tubular necrosis
The mechanisms of kidney injury include direct tubular epithelial cell toxicity with increased
tubular permeability and necrosis, as well as arterial vasoconstriction and ischemic injury.
Overall, the combined effects of increased cell energy and oxygen requirements because of
greater cell membrane permeability, and reduced cellular oxygen delivery because of renal
vasoconstriction, result in renal medullary tubular epithelial cell necrosis and kidney injury
Direct cell membrane actions increase permeability, as well as indirect effects secondary to
activation of intrarenal mechanisms (tubuloglomerular feedback) and/or release of mediators
(thromboxane A2).
The back-leak of hydrogen ions in the collecting duct leads to distal renal tubular acidosis
(dRTA).
14
15. Amphotericin B binds to sterols in cell membranes, thereby creating pores that
compromise membrane integrity and increase membrane permeability.
It binds not only to ergosterol in fungal cell walls but also to cholesterol in human cell
membranes; this is what accounts for its nephrotoxicity.
The prediction of the kidney for amphotericin B toxicity is unclear as little drug is excreted
by the kidneys.
Toxicity is manifested by increased renal vascular resistance, depression of RBF and
GFR, and altered tubular function that reflects the capacity of this drug to interact with
cholesterol-containing membranes and increase membrane permeability to ions
including potassium, hydrogen, calcium, and magnesium.
Lipid-based preparations of amphotericin B decrease but do not eliminate the
nephrotoxicity compared with traditional amphotericin B.
This may be due to a direct nephrotoxic effect of the conventional preparation.
15
17. Risk Factors
CKD
Higher average daily doses
Volume depletion
Concomitant administration of diuretics and other nephrotoxins
(cyclosporine in particular).
Rapid infusions of amphotericin B [A recent comparison of 24-hour
continuous infusions with conventional 4- hour infusions revealed a
significant reduction of toxicity, attributed to decreased “pretubular” effects
(e.g., effects on renal blood flow and GFR).]
17
18. Prevention
Several liposomal amphotericin B formulations are now available and
should be used in most high-risk patients as they have been reported to
reduce nephrotoxicity by enhancing drug delivery to sites of infection,
thereby reducing exposure of mammalian cell membranes.
Nephrotoxicity can also be minimized by limiting the cumulative dose and
avoiding concomitant administration of other nephrotoxins, particularly
cyclosporine.
Additionally, providing hydration with 1 L intravenous 0.9% sodium chloride
daily during the course of therapy appears to reduce toxicity.
18
19. TRIMETHOPRIM
Acute interstitial nephritis (AIN) is thought to be the usual mechanism.
Trimethoprim (TMP) is known to cause reversible increases in serum creatinine, reportedly
by inhibiting its renal tubular secretion without causing a change in the glomerular filtration
rate.
Patients with an initially normal renal function also needed to have an increase in BUN of
10 mg/dL, and those with chronic kidney disease needed to exhibit an increase in BUN of
≥50% in order to be classified in the AKI group
The increase in serum creatinine causes an apparent decrease in the
calculated creatinine clearance.
Renal disorders associated with its use include decreased creatinine secretion,
interstitial nephritis, and hypernatremia
Hyperkalemia has been demonstrated to occur with the administration of both high and
standard dosages of trimethoprim
19
20. Trimethoprim reduces renal potassium excretion through the competitive inhibition of epithelial
sodium channels in the distal nephron, in a manner identical to the potassium-sparing diuretic
amiloride
Hyperkalemia and non-oliguric renal failure has been associated with trimethoprim use
Trimethoprim alone can cause an important but reversible increase in serum creatinine
concentration in acute uncomplicated cystitis and in chronic renal failure
20
21. RISK FACTORS
Acute uncomplicated cystitis
Chronic renal failure
Patients with hypertension and diabetes mellitus had an increased risk
for AKI, especially if these conditions were poorly controlled
Disturbances in potassium homeostasis:
Hyopoaldosteronism
Treatment with medications that impair renal potassium excretion
21
22. PREVENTION
Recognition of patients at risk of developing hyperkalemia as well as
proper dosage selection of trimethoprim for the patient's prevailing
glomerular filtration rate
Volume repletion with isotonic fluids
Other therapies specific to hyperkalemia
Discontinuation of the drug
In circumstances where continued treatment with trimethoprim is
required, induction of high urinary flow rates with intravenous fluids
and a loop diuretic, as well as alkalinisation of the urine, have been
shown to block the antikaliuretic effect of trimethoprim on distal
nephron cells
22
23. B – LACTAM ANTIBIOTICS
Acute interstitial nephritis (AIN) is thought to be the usual mechanism.
The nephrotoxic beta-lactam antibiotics cause acute proximal tubular necrosis.
Significant renal toxicity, which has been rare with the penicillins and uncommon with the cephalosporins, with a
greater risk with the penems.
The beta-lactams most nephrotoxic are cephaloridine, cephaloglycin, and imipenem
Antibiotic concentrations in the tubular cell, determined by the net effects of contraluminal secretory transport and
subsequent movement across the luminal membrane, make the proximal tubule the sole target of injury, and are
important determinants of the nephrotoxic potentials of different beta-lactams
Mechanisms of injury include:
(1) Transport into the tubular cell, mainly through the antiluminal organic anion secretory carrier;
(2) Acylation of target proteins, causing respiratory toxicity by inactivation of mitochondrial anionic substrate carriers;
and
(3) Lipid peroxidation.
Depressed mitochondrial respiration secondary to acylation of the mitochondrial transporter for succinate has been
implicated in the pathogenesis of toxicity caused by cephalosporins and carbapenems
Lipid peroxidation appears to play a major role in the toxicity of cephaloridine.
23
24. Cephaloridine has several unique properties, probably all caused by its pyridinium
side-group:
(1) Its secretory transport into the tubular cell is followed by minimal cell to luminal fluid
movement, resulting in extreme intracellular sequestration;
(2) It is the only beta-lactam shown to cause significant oxidative injury;
(3) It has a limited ability to attack the mitochondrial carriers for pyruvate and the short-
chain fatty anions.
Cephaloglycin and imipenem undergo less intracellular trapping than cephaloridine, but
have sufficient tubular cell uptake, reactivity, and generalized toxicity to mitochondrial
substrate carriers to be severely nephrotoxic.
Several of the cephalosporin and carbapenem antibiotics produce acute renal failure
when given in large single doses.
Imipenem, the first carbapenem released for c1inical use, and the one with the best-
described nephrotoxic potential
24
25. Clinical presentation
Clinical signs present approximately 14 days after initiation of therapy
Fever, maculopapular rash, eosinophilia, pyuria and haematuria, low-level
proteinuria, and oliguria
Systemic hypersensitivity findings of fever, rash, eosinophilia, and
eosinophiluria
Eosinophiluria, an important marker of drug-induced AIN, is frequently absent,
possibly because of fragility of eosinophils in urine and inadequate laboratory
methodology
Anaemia, leucocytosis, and elevated immunoglobulin E levels may occur.
Tubular dysfunction may be manifested by acidosis, hyperkalaemia, salt
wasting, and concentrating defects.
25
26. RISK FACTORS AND PREVENTION
Concomitant administration with
Aminoglycosides
Renal ischemia and
Endotoxemia
Prevention of nephrotoxicity of imipenem:
Use cilastatin along with imipenem
26
27. FLUROQUINOLONES
Nephrotoxic reactions to ciprofloxacin appear to be unusual but potentially serious.
It has previously been reported that fluoroquinolones could cause acute renal failure
(ARF) after the ingestion of large quantities, but it is now recognized that therapeutic
doses of fluoroquinolones can also cause renal injury.
Allergic interstitial nephritis (AIN) is thought to be the most common cause and is
attributed to hypersensitivity reaction type III, while a ciprofloxacin overdose often
causes acute tubular necrosis (ATN);
The normal dose range for ciprofloxacin is between 500 and 750 mg/12 h).
Fluoroquinolones have also been reported to cause granulomatous interstitial
nephritis, characterized by infiltration of the renal tissue by histiocytes and T
lymphocytes, leading to the formation of granulomas
27
28. Ciprofloxacin causes crystal nephropathy
Ciprofloxacin crystals precipitate in alkaline urine and provoke renal failure
through intra-tubular precipitation.
Ciprofloxacin can cause crystalluria in alkaline urine especially at pH>7.3
The combined use of fluoroquinolones and renin-angiotensin system
blockers was associated with a greater risk for acute kidney injury
28
29. VANCOMYCIN
Vancomycin has been used for over 60 years to treat methicillin-resistant S. aureus and
various resistant gram-positive infections. This antibiotic is commonly linked to
nephrotoxicity, leading to the need for aggressive monitoring with regularly measured
vancomycin trough levels
Vancomycin is eliminated primarily through glomerular filtration and active tubular
secretion.
The half-life in adults with normal renal function is 4 to 8 hours.
Vancomycin-induced acute kidney injury is histologically characterized by acute
interstitial nephritis and/or acute tubular necrosis.
use of the antibiotic causes oxidative effects on the proximal renal tubule resulting in
renal tubular ischemia.
The drug has also been shown to interfere with the normal reabsorption function of the
proximal renal tubule epithelium and alter the mitochondrial function of these cells.
Ultimately, vancomycin-induced renal toxicity is likely due to a combination of these
oxidative effects and allergic interstitial nephritis.
29
31. RISK FACTORS
Vancomycin exposure related
factors
• Doses of vancomycin in excess of 4 g/day
• Prolonged duration of treatment
• Larger vancomycin exposures, such as troughs >15 mg/L
• Treatment with vancomycin beyond 1 week increases the incidence of
nephrotoxicity from 6% to 21%, and the incidence is close to 30% with more than
2 weeks of therapy.
Host-related factors • Previous history of acute kidney injury
• Preexisting renal insufficiency
• Sepsis
• Critical illnesses.
use of concurrent nephrotoxins • Loop diuretics
• Acyclovir
• Amphotericin B
• Aminoglycosides (The concurrent use of aminoglycosides with vancomycin has
been associated with a 20% to 30% increase in renal injury)
31
32. PREVENTION
Most mild cases of vancomycin nephrotoxicity resolve upon discontinuation of the
medication.
Aggressive drug elimination is indicated in patients with severely elevated plasma
vancomycin concentrations compounded by impaired clearance due to oliguria, as
this further increases the risk of permanent renal damage.
Standard membrane dialysis is ineffective in clearing large mass molecules such as
vancomycin, but high-flux hemodialysis allows for improved elimination of large
molecules, with a reported vancomycin removal rate of up to 79%
Oral prednisone and high-flux hemodialysis have led to the successful recovery of
renal function in some biopsy-proven cases.
32
33. ACYCLOVIR
Acyclovir is an important antiviral agent in the therapy of herpes simplex and varicella
zoster virus infections. Although the drug is well tolerated, severe nephrotoxicity, which
often leads to acute renal failure, has been observed in patients
A diagnosis of drug-related acute tubulointerstitial nephritis with focal tubular necrosis
was made.
Acyclovir-induced renal failure occurs in approximately 12–48 % of cases.
The optimal usage of acyclovir is very important in order to avoid its potentially life-
threatening complications.
Acyclovir-induced nephrotoxicity is typically evident by an increase in the plasma
creatinine level, abnormal urine sediment, or acute renal injury.
Acyclovir is rapidly excreted in the urine via glomerular filtration and tubular secretion, and
reaches high concentrations in the tubular lumen.
33
34. Renal excretion of unchanged drug reaches approximately
60–90 % .
Acyclovir is relatively insoluble in the urine, particularly in
the distal tubular lumen.
Rapid intravenous administration of high-dose acyclovir is
associated with high luminal concentrations of this drug and
the intratubular precipitation of crystals can cause renal
injury.
Typically, crystalluria develops within 24–48 h of the
initiation of acyclovir therapy.
Severe intraparenchymal precipitation of crystals can cause
interstitial congestion and hemorrhage, leading to a
decrease of renal blood flow
34
35. RISK FACTORS AND PREVENTION
RISK FACTORS
The administration of high doses of acyclovir (≥1500 mg/m2 per day) with other nephrotoxic agents
pre-existing renal disease
dehydration
Rapid intravenous administration of high-dose acyclovir
PREVENTION
Acyclovir dose should be reduced in patients with underlying renal insufficiency.
Slow drug infusion, over 1–2 h
Adequate fluid replacement
Induction of high urinary flow rates (100–150 ml/h) should be encouraged in order to prevent crystal
precipitation and subsequent tubular obstruction
Initiation of dialysis when indicated.
Hemodialysis removes substantial amounts of acyclovir.
Peritoneal dialysis is less effective and should not be used
35
36. TETRACYCLINS
Kidney damage:
It is a risk only in the presence of existing kidney disease.
All tetracyclines, except doxycycline, accumulate and enhance renal
failure.
A reversible Fanconi syndrome like condition is produced by outdated
tetracyclines.
This is caused by degraded products—epitetracycline, anhydrotetracycline
and epianhydrotetracycline which damage proximal tubules.
Exposure to acidic pH, moisture and heat favours such degradation.
36